QPI-1002

DRUG2 trials

Sponsors

Quark Pharmaceuticals

Conditions

Acute Kidney InjuryDelayed Graft Function

Phase 2

A Study to Evaluate Efficacy and Safety of QPI-1002 for Prevention of Acute Kidney Injury Following Cardiac Surgery

CompletedNCT02610283

Quark PharmaceuticalsAcute Kidney Injury

Start: 2015-12-31End: 2018-04-30Updated: 2019-01-10

Phase 3

QPI-1002 for Prevention of Delayed Graft Function in Recipients of an Older Donor Kidney Transplant

CompletedNCT02610296

Quark PharmaceuticalsDelayed Graft Function

Start: 2016-03-01End: 2019-01-08Updated: 2020-05-13

Related Papers

Teprasiran, a Small Interfering RNA, for the Prevention of Acute Kidney Injury in High-Risk Patients Undergoing Cardiac Surgery: A Randomized Clinical Study

Circulation2021-09-0390 citations